PHR Stock Analysis: Phreesia | NYSE
Health Information Services | NYSE, USA | Market Cap: 671m USD | 12M Return: -51.9% | US71944F1066 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 6.64M
Qual. Beats: 0
Rev. Trend: 99.6%
Qual. Beats: 2
Warnings
Tailwinds
No distinct edge detected
Seasonality 7.2 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Phreesia, Inc. (NYSE: PHR) is a U.S.-based healthcare technology company that operates an integrated SaaS platform combining patient intake software with payment processing for providers in the United States and Canada. The company sits within the Health Care Technology sub-industry (GICS), a segment that has expanded as providers shift administrative workflows - such as registration, eligibility checks, and point-of-service payments - from paper-based to digital, self-service models. Phreesia has been public since its July 2019 IPO and currently carries a small-cap market capitalization of roughly $625 million USD.
The platform bundles several solution categories: AI-enabled appointment scheduling and referral management, voice- and text-based patient communications, embedded payment processing with patient financing, digital intake and clinical data capture, patient engagement tools, and analytics. Phreesia also sells proprietary hardware - PhreesiaPads (self-service tablets) and Arrivals Kiosks - which is a distinguishing feature within the healthcare SaaS space, where most competitors are software-only. Combining hardware with software and payments creates a recurring revenue mix typical of vertical SaaS plays, while also positioning the company to capture a share of the patient payment processing market that has historically been served by legacy merchant processors.
Phreesias customer base spans ambulatory practices, health systems, and hospitals, and extends to life sciences companies, government agencies, and not-for-profit organizations - a breadth of end markets that diversifies revenue across provider and non-provider buyers. The company was incorporated in 2005 and is headquartered in Wilmington, Delaware.
- Subscription revenue growth drives healthcare client expansion
- Payment processing volumes scale as patient intake digitizes
- Life sciences pharma advertising demand boosts margin profile
| Net Income: 10.4m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 4.31 > 1.0 |
| NWC/Revenue: 21.60% < 20% (prev 26.13%; Δ -4.53% < -1%) |
| CFO/TA 0.14 > 3% & CFO 91.4m > Net Income 10.4m |
| Net Debt (-3.50m) to EBITDA (56.1m): -0.06 < 3 |
| Current Ratio: 1.76 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.5m) vs 12m ago 5.40% < -2% |
| Gross Margin: 63.55% > 18% (prev 68.02%; Δ -4.47% > 0.5%) |
| Asset Turnover: 96.21% > 50% (prev 110.0%; Δ -13.84% > 0%) |
| Interest Coverage Ratio: 1.78 > 6 (EBIT TTM 19.0m / Interest Expense TTM 10.7m) |
| A: 0.17 (Total Current Assets 253.5m - Total Current Liabilities 143.8m) / Total Assets 647.0m |
| B: -1.23 (Retained Earnings -794.3m / Total Assets 647.0m) |
| C: 0.04 (EBIT TTM 19.0m / Avg Total Assets 527.8m) |
| D: 1.35 (Book Value of Equity 371.9m / Total Liabilities 275.1m) |
| Altman-Z'' = -1.23 = CCC |
| DSRI: 1.55 (Receivables 134.3m/76.8m, Revenue 507.8m/449.7m) |
| GMI: 1.07 (GM 68.02% / 63.55%) |
| AQI: 1.45 (AQ_t 0.58 / AQ_t-1 0.40) |
| SGI: 1.13 (Revenue 507.8m / 449.7m) |
| TATA: -0.13 (NI 10.4m - CFO 91.4m) / TA 647.0m) |
| Beneish M = -2.16 (Cap -4..+1) = BB |
As of October 16, 2026, the stock is trading at USD 11.04 with a total of 996,121 shares traded. Over the past week, the price has changed by +3.56%, over one month by +6.67%, over three months by +2.60% and over the past year by -51.85%.
Current recommended Stop Loss: 10.50 (which is 4.9% or 1.4 ATR below the current price).
Phreesia has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy PHR.
- StrongBuy: 8
- Buy: 2
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 14.1 | 28% |
P/E Trailing = 63.5882
P/E Forward = 12.0192
P/S = 1.3214
P/B = 1.6158
Revenue TTM = 507.8m USD
EBIT TTM = 19.0m USD
EBITDA TTM = 56.1m USD
Long Term Debt = 61.2m USD (from longTermDebt, last quarter)
Short Term Debt = 6.11m USD (from shortTermDebt, last quarter)
Debt = 69.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 1.50m
Net Debt = -3.50m USD (calculated: Debt 69.4m - CCE 72.9m)
Enterprise Value = 667.5m USD (671.0m + Debt 69.4m - CCE 72.9m)
Interest Coverage Ratio = 1.78 (Ebit TTM 19.0m / Interest Expense TTM 10.7m)
EV/FCF = 8.61x (Enterprise Value 667.5m / FCF TTM 77.5m)
FCF Yield = 11.61% (FCF TTM 77.5m / Enterprise Value 667.5m)
FCF Margin = 15.26% (FCF TTM 77.5m / Revenue TTM 507.8m)
Net Margin = 2.06% (Net Income TTM 10.4m / Revenue TTM 507.8m)
Gross Margin = 63.55% ((Revenue TTM 507.8m - Cost of Revenue TTM 185.1m) / Revenue TTM)
Gross Margin QoQ = 58.84% (prev 59.21%)
Tobins Q-Ratio = 1.03 (Enterprise Value 667.5m / Total Assets 647.0m)
Interest Expense / Debt = 15.35% (Interest Expense 10.7m / Debt 69.4m)
Taxrate = 40.78% (1.32m / 3.24m)
NOPAT = 11.3m (EBIT 19.0m * (1 - 40.78%))
Current Ratio = 1.76 (Total Current Assets 253.5m / Total Current Liabilities 143.8m)
Debt / Equity = 0.19 (Debt 69.4m / totalStockholderEquity, last quarter 371.9m)
Debt / EBITDA = -0.06 (Net Debt -3.50m / EBITDA 56.1m)
Debt / FCF = -0.05 (Net Debt -3.50m / FCF TTM 77.5m)
Total Stockholder Equity = 347.1m (last 4 quarters mean from totalStockholderEquity)
RoA = 1.98% (Net Income 10.4m / Total Assets 647.0m)
RoE = 3.01% (Net Income TTM 10.4m / Total Stockholder Equity 347.1m)
RoCE = 4.65% (EBIT 19.0m / Capital Employed (Equity 347.1m + L.T.Debt 61.2m))
RoIC = 2.33% (NOPAT 11.3m / Invested Capital 483.9m)
WACC = 11.19% (E(671.0m)/V(740.4m) * Re(11.41%) + D(69.4m)/V(740.4m) * Rd(15.35%) * (1-Tc(0.41)))
Discount Rate = 11.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 97.95 | Cagr: 4.42%
[DCF] Terminal Value 69.35% ; FCFF base≈59.0m ; Y1≈67.7m ; Y5≈99.6m
[DCF] Fair Price = 16.11 (EV 996.4m - Net Debt -3.50m = Equity 999.9m / Shares 62.1m; r=11.19% [WACC]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.33 | # QB: 0
Revenue Correlation: 99.62 | Revenue CAGR: 15.69% | SUE: 1.85 | # QB: 2
EPS current Quarter (2026-10-31): EPS=0.37 | Chg30d=+2.15% | Revisions=+18% | Analysts=10
EPS current Year (2027-01-31): EPS=1.28 | Chg30d=+3.08% | Revisions=-42% | GrowthEPS=-1.0% | GrowthRev=+7.3%
EPS next Year (2028-01-31): EPS=1.61 | Chg30d=+0.39% | Revisions=-10% | GrowthEPS=+26.1% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -15% (up=10, down=14)